A Study of SHR-A1403 in Patients With Advanced Solid Tumor
Status:
Unknown status
Trial end date:
2020-11-01
Target enrollment:
Participant gender:
Summary
SHR-A1403 is a humanized IgG2, anti-C-Met monoclonal antibody conjugated to microtubule
inhibitor (c-Met ADC).The aim of this study is to assess the safety and tolerability of
SHR-A1403，to define the dose limited toxicity（DLT）and the maximum tolerated dose (MTD)，to
evaluate the pharmacokinetics of SHR-A1403，to assess the antitumor activity of SHR-A1403 in
patients with advanced solid tumors preliminarily and to recommend the reasonable dosage
regimen of SHR-A1403 for the follow-up clinical trial.